Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

3
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (1)

Searched Name

Chongqing Talents-Exceptional Young Talents Project

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number

Citation Analysis

Huang B, Ren J, Ma Q, Yang F, Pan X, Zhang Y, Liu Y, Wang C, Zhang D, Wei L, Ran L, Zhao H, Liang C, Wang X, Wang S, Li H, Ning H, Ran A, Li W, Wang Y, Xiao B. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway. Mol Cancer 2024;23:34. [PMID: 38360682 PMCID: PMC10870583 DOI: 10.1186/s12943-024-01940-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 01/12/2024] [Indexed: 02/17/2024] Open

Abstract

BACKGROUND

Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer with high aggressive phenotype and poor prognosis. Accumulating evidence suggests that circRNAs have been identified as pivotal mediators in cancers. However, the role of circRNAs in ccRCC progression remains elusive.

METHODS

The differentially expressed circRNAs in 4 paired human ccRCC and adjacent noncancerous tissues ccRCC were screened using circRNA microarrays and the candidate target was selected based on circRNA expression level using weighted gene correlation network analysis (WGCNA) and the gene expression omnibus (GEO) database. CircPDHK1 expression in ccRCC and adjacent noncancerous tissues (n = 148) were evaluated along with clinically relevant information. RT-qPCR, RNase R digestion, and actinomycin D (ActD) stability test were conducted to identify the characteristics of circPDHK1. The subcellular distribution of circPDHK1 was analyzed by subcellular fractionation assay and fluorescence in situ hybridization (FISH). Immunoprecipitation-mass spectrometry (IP-MS) and immunofluorescence (IF) were employed to evaluate the protein-coding ability of circPDHK1. ccRCC cells were transfected with siRNAs, plasmids or lentivirus approach, and cell proliferation, migration and invasion, as well as tumorigenesis and metastasis in nude mice were assessed to clarify the functional roles of circPDHK1 and its encoded peptide PDHK1-241aa. RNA-sequencing, western blot analysis, immunoprecipitation (IP) and chromatin immunoprecipitation (ChIP) assays were further employed to identify the underlying mechanisms regulated by PDHK1-241aa.

RESULTS

CircPDHK1 was upregulated in ccRCC tissues and closely related to WHO/ISUP stage, T stage, distant metastasis, VHL mutation and Ki-67 levels. CircPDHK1 had a functional internal ribosome entry site (IRES) and encoded a novel peptide PDHK1-241aa. Functionally, we confirmed that PDHK1-241aa and not the circPDHK1 promoted the proliferation, migration and invasion of ccRCC. Mechanistically, circPDHK1 was activated by HIF-2A at the transcriptional level. PDHK1-241aa was upregulated and interacted with PPP1CA, causing the relocation of PPP1CA to the nucleus. This thereby inhibited AKT dephosphorylation and activated the AKT-mTOR signaling pathway.

CONCLUSIONS

Our data indicated that circPDHK1-encoded PDHK1-241aa promotes ccRCC progression by interacting with PPP1CA to inhibit AKT dephosphorylation. This study provides novel insights into the multiplicity of circRNAs and highlights the potential use of circPDHK1 or PDHK1-241aa as a therapeutic target for ccRCC.

Collapse

Affiliation(s)

Bo Huang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, 563006, P.R. China
Junwu Ren College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Qiang Ma College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Feifei Yang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Xiaojuan Pan College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Yuying Zhang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Yuying Liu College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Cong Wang Department of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China
Dawei Zhang Department of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China
Ling Wei Department of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China
Lingyu Ran Department of Kidney, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China
Hongwen Zhao Department of Kidney, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China
Ce Liang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Xiaolin Wang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Shiming Wang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Haiping Li College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Hao Ning College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Ai Ran College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China
Wei Li Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, 400030, P.R. China.
Yongquan Wang Department of Urology, Southwest Hospital, Army Medical University, Chongqing, 400038, P.R. China.
Bin Xiao College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P.R. China.

Collapse

Wang X, Liang C, Wang S, Ma Q, Pan X, Ran A, Qin C, Huang B, Yang F, Liu Y, Zhang Y, Ren J, Ning H, Li H, Jiang Y, Xiao B. RNA Binding Protein PTBP1 Promotes the Metastasis of Gastric Cancer by Stabilizing PGK1 mRNA. Cells 2024;13:140. [PMID: 38247832 PMCID: PMC10814388 DOI: 10.3390/cells13020140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 12/31/2023] [Accepted: 01/09/2024] [Indexed: 01/23/2024] Open

Affiliation(s)

Xiaolin Wang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Ce Liang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Shimin Wang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Qiang Ma College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Xiaojuan Pan College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Ai Ran College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Changhong Qin College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Bo Huang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.) Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, China
Feifei Yang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Yuying Liu College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Yuying Zhang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Junwu Ren College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Hao Ning College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Haiping Li College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Yan Jiang College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)
Bin Xiao College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; (X.W.); (C.L.); (S.W.); (Q.M.); (X.P.); (A.R.); (C.Q.); (B.H.); (F.Y.); (Y.L.); (Y.Z.); (J.R.); (H.N.); (H.L.); (Y.J.)

Collapse

Yang F, Ma Q, Huang B, Wang X, Pan X, Yu T, Ran L, Jiang S, Li H, Chen Y, Liu Y, Liang C, Ren J, Zhang Y, Wang S, Li W, Xiao B. CircNFATC3 promotes the proliferation of gastric cancer through binding to IGF2BP3 and restricting its ubiquitination to enhance CCND1 mRNA stability. J Transl Med 2023;21:402. [PMID: 37340423 DOI: 10.1186/s12967-023-04235-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 05/28/2023] [Indexed: 06/22/2023] Open

Abstract

BACKGROUND

Insulin like growth factor II mRNA binding protein 3 (IGF2BP3) is an RNA binding protein with multiple roles in regulation of gene expression at the post-transcriptional level and is implicated in tumorigenesis and progression of numerous cancers including gastric cancer (GC). Circular RNAs (circRNAs) are a diverse endogenous noncoding RNA population that have important regulatory roles in cancer. However, circRNAs that regulate the expression of IGF2BP3 in GC is largely unknown.

METHODS

CircRNAs that bound to IGF2BP3 were screened in GC cells using RNA immunoprecipitation and sequencing (RIP-seq). The identification and localization of circular nuclear factor of activated T cells 3 (circNFATC3) were identified using Sanger sequencing, RNase R assays, qRT-PCR, nuclear-cytoplasmic fractionation and RNA-FISH assays. CircNFATC3 expression in human GC tissues and adjacent normal tissues were measured by qRT-PCR and ISH. The biological role of circNFATC3 in GC was confirmed by in vivo and in vitro experiments. Furthermore, RIP, RNA-FISH/IF, IP and rescue experiments were performed to uncover interactions between circNFATC3, IGF2BP3 and cyclin D1 (CCND1).

RESULTS

We identified a GC-associated circRNA, circNFATC3, that interacted with IGF2BP3. CircNFATC3 was significantly overexpressed in GC tissues and was positively associated with tumor volume. Functionally, the proliferation of GC cells decreased significantly after circNFATC3 knockdown in vivo and in vitro. Mechanistically, circNFATC3 bound to IGF2BP3 in the cytoplasm, which enhanced the stability of IGF2BP3 by preventing ubiquitin E3 ligase TRIM25-mediated ubiquitination, thereby enhancing the regulatory axis of IGF2BP3-CCND1 and promoting CCND1 mRNA stability.

CONCLUSIONS

Our findings demonstrate that circNFATC3 promotes GC proliferation by stabilizing IGF2BP3 protein to enhance CCND1 mRNA stability. Therefore, circNFATC3 is a potential novel target for the treatment of GC.

Collapse

Affiliation(s)

Feifei Yang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Qiang Ma College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China Department of Clinical Laboratory, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, People's Republic of China
Bo Huang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Xiaolin Wang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Xiaojuan Pan College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Ting Yu Department of Clinical Laboratory, The 89th Hospital of The People's Liberation Army, Weifang, 261000, People's Republic of China
Lingyu Ran Department of Kidney, Southwest Hospital, Army Medical University, Chongqing, 400038, People's Republic of China
Shan Jiang Institute for Advanced Study, Shenzhen University, Shenzhen, 518055, People's Republic of China
Haiping Li College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Ye Chen College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Yuying Liu College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Ce Liang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Junwu Ren College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Yuying Zhang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Shimin Wang College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China
Wei Li Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, 400030, People's Republic of China.
Bin Xiao College of Pharmacy, Chongqing Medical University, Chongqing, 400016, People's Republic of China.

Collapse